Disability treatment

TrialSpark licenses sprifermin, an investigational first-class disease-modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio

-High Line Bio will focus on the treatment of osteoarthritis, a disease affecting over 230 million patients worldwide and without disease-modifying therapy -High Line Bio will leverage TrialSpark’s unique ability to develop treatments faster and more efficiently for patients than traditional pharmaceutical companies through its proprietary technology-based clinical trials engine …

Read More »

Frankincense treatment for multiple sclerosis?

primary 1 million people suffer from MS in Europe Globally, this disease affects 2.8 million patients. 110,000 people suffer from multiple sclerosis in France, according to National Institute of Health and Medical Research (Inserm). It is the leading cause of severe non-traumatic disability in young adults. Currently, there is no …

Read More »

The Disability Treatment Learning Market To See Exponential Growth During The Forecast Period 2021-2028, Key Players – CogniFit Eli Lilly & Company

New York, United States: In this report, “Global Learning Disability Treatment Market revenue is expected to increase substantially over the forecast period 2021-2028, Decisive Markets Insights reports that the market has experienced impressive growth. A comprehensive market analysis is provided throughout the report. The report provides a concise introduction to …

Read More »